IUX MARKETS LTD WINS BIG AT GLOBAL BRAND AWARDS 2025
The Global Brand Awards recognises outstanding achievements across various industries worldwide. IUX Market Ltd received this award for its continued efforts in providing innovative trading solutions, ultra-low spreads, and advanced risk management tools, ensuring a secure, transparent, and cost-effective trading experience for clients globally.
Jay Reddy, CEO of Global Brands Magazine, commented, "We are thrilled to honour IUX Markets with the 2025 awards for Best Risk Management Technology Forex Broker and Best Forex Broker for Low Spreads in Asia. IUX's unwavering commitment to delivering ultra-low spreads, cutting-edge risk management tools, and a client-centric trading experience sets a remarkable standard in the industry. Congratulations to the IUX team for their outstanding achievements and continued innovation "
Commenting on winning the award, Alex Delarue, Regional Commercial Director (APAC), IUX Markets Ltd, commented, "We're thrilled to receive the recognition from Global Brands Magazine with the awards for Best Risk Management Technology and Best Forex Broker for Low Spreads in Asia 2025. It's a great testament to the hard work and dedication of everyone at IUX. These awards inspire us to keep pushing boundaries and improving the trading experience for our clients. At IUX, our goal has always been to provide a platform that combines security, technology, and affordability, and it's amazing to see that our efforts are being recognized. We're excited for what's ahead and will continue to focus on delivering the best possible service to our traders."
ABOUT IUX MARKETS LTD
IUX was established in 2016 as a provider of online CFD trading services. The company places great importance on its clients' trading journey and remains committed to continuously refining its technology, personalized services, and educational resources. Over the years, as the industry and client expectations have evolved, IUX has firmly positioned itself as a trusted and leading regulated broker.
ABOUT GLOBAL BRANDS MAGAZINE (ENGLAND)
Global Brands Magazine (GBM) is one of the largest Brands publication in the world, leading the way in delivering insights, news, and opinions on brands shaping the future of their industries. Based in the UK, the magazine keeps readers informed about 'best-in-class' brands worldwide. Each year, GBM recognizes companies that demonstrate innovation, exceptional service, and consumer-focused solutions in their respective industries.
With over 8.4 million annual visitors, and 14 million page views, GBM is the world's premier Brand magazine. The magazine also boasts a robust social media presence, engagement including 35k+ Facebook followers, 20k+ Instagram followers, 25k+ Twitter followers, and 4k+ LinkedIn followers.
ABOUT THE GLOBAL BRAND AWARDS
The Global Brand Awards celebrate excellence in brand performance, recognising companies and organisations that excel in quality, innovation, and customer-centric services across various sectors, including finance, education, hospitality, technology, and more. More than 10,000 companies were evaluated in 2024 for the Global Brand Awards.
The Global Brand Awards events were held at some of the most iconic properties in the world, including The Address Downtown, Waldorf Astoria, Emperors Palace, JW Marriot Marquis, Galaxy Macau, The Athenee Hotel, to name a few. The next awards ceremony will take place on the 13th of June 2025 at the Grand Hyatt in Dubai, United Arab Emirates.
For a complete list of the winners of the Global Brand Awards, please visit: https://www.globalbrandsmagazine.com/brand-awards-winners/.
To nominate your company or leader for the Global Brand Awards 2025, visit: https://www.globalbrandsmagazine.com/nomination-form/
Logo: https://mma.prnewswire.com/media/2648066/5320844/GBM_Awards_2025_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/iux-markets-ltd-wins-big-at-global-brand-awards-2025-302456483.html
SOURCE Global Brands Magazine
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
08-08-2025
- CNBC
How dealmaking king Goldman Sachs aims to dominate another corner of Wall Street
Goldman Sachs has long been considered the king of Wall Street dealmaking. Now, the bank is increasing its focus on another target: managing money for wealthy clients and institutions. Investment banking services, like underwriting initial public offerings (IPO) and advising mergers and acquisitions (M & A), have long been Goldman's bread and butter. In fact, the firm was ranked No. 1 in overall global M & A activity for the first seven months of 2025, capturing 32% of market share among its financial peers, according to LSEG data. Most recently, Goldman has had its hand in a number of high-profile initial public offerings, too, such as Nvidia chips-for-rent company CoreWeave , trading platform eToro , and fintech company Chime. But management sees a big opportunity in its much-smaller asset and wealth management (AWM) division. Speaking to CNBC, Marc Nachmann, Goldman's global head of asset and wealth management, said the company has a plan to grow this business — which includes portfolio construction, risk management, financial planning and other investment services — and challenge its banking peers in a less-crowded corner of Wall Street. "There's still an opportunity to take market share and be a winner in this game," he said. Indeed, Goldman's not alone in this pursuit. Morgan Stanley , for example, has been working for years to hit its goal of $10 trillion in total client assets across its wealth and investment management division, which was set under former CEO James Gorman in 2022 and continues under current CEO Ted Pick. The push for Goldman would also help to further diversify the firm's revenue streams. Investment banking makes up more than two-thirds of overall sales, but these incomes can be volatile and cyclical. That was last seen in 2020 when the Covid-19 pandemic caused a huge disruption to Wall Street dealmaking, which the industry is still recovering from. In contrast, revenue from asset and wealth management services are often fee-based and less impacted by short-term market fluctuations. In a wide-ranging interview with Nachmann, we also talked about Goldman's generative artificial intelligence ambitions, the regulatory backdrop under President Donald Trump , and Wall Street's push into alternative assets, which the White House wants to allow into retirement accounts. This interview has been edited for clarity and length. A lot of Wall Street is focused on Goldman as a play on the rebound in investment banking, but I'm interested in looking into growth and expansion in areas outside of the GBM division, specifically your asset and wealth management businesses. How does AWM complement Goldman's overall business mix? Nachmann: When you take it back to the big picture, one of the things that has helped tell our story better is that in the beginning of 2023 we had our investor day at the end of February. We reorganized the way we report and manage ourselves into these two big areas, right? So, you have GBM and AWM. GBM is the combination of the trading business and the investment banking business. I'd say it's the long-established businesses. Both of these businesses are pretty concentrated when you think about the key players. When you think about both trading and banking between Goldman Sachs, JPMorgan , and Morgan Stanley, that's a huge percentage of the market. And we've been a leader there for a long time. I'd also say overall GBM is a capital-intensive business, too, right? So, it requires a good amount of balance sheet. I think it's a good return business, but it has some cyclicality in it. So, you see the capital markets activity, IPO calendars going up and down, M & A volumes going up and down, and trading volumes up and down. That's a big 70% of our revenue from there. When you look at AWM, generally speaking, we have fee revenues that are sticky, durable, and generally speaking, good secular growth with both asset management and wealth. There's less cyclicality. So, now you have less cyclical, less capital-intensive, more durable, sticky revenues, but it's much more fragmented. And it's not the same thing where you don't have a Goldman, JPMorgan or Morgan Stanley who owns a huge proportion. There's still an opportunity to take market share and be a winner in this game. I think we really simplified the firm into these two buckets. And given that AWM has this underlying secular growth, as well as the opportunity to continue to build more market share, it's the growth part of the firm. I say that with all due respect to my colleagues in GBM. They of course want to grow too, but I'm just saying in terms of long-term growth, it's really on the AWM side. Goldman Sachs CEO David Solomon emphasized during the conference call that Goldman is "particularly focused on thinking about ways to accelerate the asset and wealth management franchise." Can you break down the firm's strategy to grow this division in a more pragmatic and practical sense? Nachmann: In a big picture way, though, the AWM business grows with more headcounts because in wealth management, if you want to cover more clients, you got to have more advisors, right? These businesses grow with headcount. So, when David says we're trying to do things to accelerate the growth, we've been allocating a good bit of human capital to AWM to allow the growth. That's a big portion of it. I think the key to that on the wealth side is really two pieces. One is to continue to grow the advisor count, right? So, we watch that very carefully. We grow our advisor count consistently. One of the things we've done is we're growing both in the U.S. and internationally. I'd say internationally we're growing faster than in the U.S., but that's because it's off a lower base. We've been very focused on growing Europe and Asia at a faster advisor hiring than in the U.S., but all three regions are growing well. So, the strategy in some sense is to continue doing what you're doing but doing it with more people. There's a strong emphasis as well on focusing on continuing to build us out in international markets. Then the second thing on the wealth side, when you look at us as a wealth manager, we are only servicing the ultra-high-net-worth segment. That's a $30 million account size and up. It makes us different from most of the other wealth managers amongst the public companies, and we're sticking to that segment. Historically, our business has been super heavy on the fee revenues around advising our clients on how to do the asset allocation and how to invest their money. We have historically not been as active on the lending side, especially if you compare us to a JPMorgan. If you look at JPMorgan, more than 50% of their wealth management revenues come from lending. For us, it's around 20% or so. We will never be at the extreme of where JPMorgan is because we want to continue to be a wealth manager in terms of giving advice on the asset side and on the investing side. But we think we can do more with our clients in helping them on the lending side. That's another growth driver for us. In what way is Goldman trying to do that on the lending side? Nachmann: So, there's two categories. There's existing clients that have lending needs that we've historically not been very focused on. So, it's doing more with existing clients on lending. And then I'd say there's a large universe of clients where lending is a precursor to a wealth relationship, where lending is very important. There's lots of wealthy people out there that are asset rich but liquidity-light. They have a lot locked up in their business. Let's say you're a hedge fund manager and all your money is in the hedge fund or you own a family business and you put most in that business. You can be very wealthy, but you don't necessarily have a ton of liquidity to just do general investing into the public markets or private markets. Those clients tend to want to have some lending facilities to give them liquidity or to allow them to invest in other things. So, whoever gives them the lending becomes their preferred partner to do their wealth management. And so given that we historically haven't been very focused on lending, those clients kind of selected themselves out and really worked more with the JPMorgans. So by more proactively focusing on the lending side, we will start doing lending with these clients. These clients over time will do all their wealth management business with us. It's a combination of doing it with more existing clients and opening up to a whole host of new clients that we haven't approached as well as we could have. Goldman announced a private credit product for retirement plans late last month. Can you tell me the origin of this offering and what the firm hopes to achieve by rolling it out? Nachmann: So, the way to think about private assets is that they are illiquid, and that is a fundamental thing. I am nervous about people who run around out there in the world – other asset managers who talk about having illiquid assets and describing them in vehicles that look like they're liquid. By definition, it doesn't work like that because private assets are illiquid. That's the whole point of them. Now, part of the reason private assets have outperformed historically is because you're basically getting a liquidity premium. If you believe asset prices in general are efficient, there has to be a reason why private assets have outperformed. One of the reasons is because you actually get paid for the fact that they are illiquid and you can't take your money out all the time. Now, another reason why you can make more money in private markets sometimes is because you can actually actively manage them. If you're a private equity firm and you buy a company, you can now make changes to the company. If you're good at it, you can actually generate excess returns because you manage this company better. That's much harder to do than buying a stock in the public market because you, as an individual shareholder, cannot really have as much impact. So, when you think about the democratization of alternatives that everybody talks about, what is a good way to do this? Well, one really good way to do this is in the retirement channel. Think about a 401(k). When you're 24 years old and you graduate from college and you start your first job and you start putting your first real dollars into a 401(k) fund, those are exactly the dollars that you should put into something that pays you for being locked up for a period of time, for being illiquid. Because at 24, you're not going to access that liquidity for decades. So, I think the retirement channel is a really interesting channel to get alternatives exposure because the fact that alternative assets are illiquid doesn't really hurt. And so that's why we're very focused on launching something into the retirement channel, specifically into target date funds. One of the big benefits is these target dates all have glide paths: they start with higher equity contributions when you're young, and as you get closer to retirement, there's more fixed income so that when you then go into retirement, you have a fixed income stream of earnings. Does this indicate an even bigger push for Goldman moving forward into alts and other private assets? Nachmann: I think we're a big alts player overall. We've stayed top five in terms of assets on the alts side. It is a bigger push that we're making consistent with what the industry is making though into this democratization of these alt products. It's one of the things we're very good at because we have this ultra-high net worth business. We have a wealth system that for many decades has been investing in alternatives. We've had, what we call it, two-legged individuals. These are individuals who've invested in alternatives versus kinds of institutions. And so we have a lot of experience with individuals investing in alternatives already. I ncorporating alts into a retirement plan probably isn't an exceptionally new idea. I'm sure people have wanted to do it for a while. The only difference now is that we have an administration that many feel will loosen up the rules. So, does the recent regulatory environment have anything to do with your decision? Nachmann: In some sense, yes. You need the right regulatory environment to be able to have alternatives in the retirement plans. As you said, this has made sense for a while. In fact, when you think about it, most pension funds, which are really kind of defined benefit programs, have big alternatives exposure. If you look at all the state pension funds, they are retirement systems. It's just a defined benefit versus a defined contribution. That has been a long-standing way of doing things. It's just that individuals in defined-contribution in their 401(k) plans have not been able to do it. A big reason for that is the regulation around it, and so I think it makes sense that the administration is now changing the regulation because individuals in their defined contribution plans should be able to have access to the same things that the big pension funds have. Goldman unveiled a firm-wide generative AI tool assistant earlier this year. How is this technology being utilized specifically in the AWM division? Nachmann : We are using it more and more. There are opportunities on the efficiency side, where generative AI can do things much faster or more efficiently than we've done historically. We've got a whole bunch of use cases that we're working on. A lot of them are at various stages. They look promising. Within the next year or two, that will really accelerate and people will understand the results much better. Can you give me an example of how currently one of Goldman's advisors may be using this tool on a day-to-day basis? Nachmann: On the wealth side, if you're an advisor and you have a bunch of clients, you can use AI to do runaway screens through your clients' portfolios. Is your asset allocation mixed in the right place as markets change? Based on what's happening to various stock prices, are you overallocated to specific stocks? Are there things missing in your asset allocation that you should be incorporating? So, there's a lot that goes into productivity enhancement. (Jim Cramer's Charitable Trust is long GS, NVDA. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Business Wire
06-08-2025
- Business Wire
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
DALLAS--(BUSINESS WIRE)-- Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. "GBM remains one of the most difficult cancers to treat, with virtually no meaningful therapeutic advances in nearly 17 years. We believe our unique combination approach has the potential to offer new hope for patients and their families." Dr. Chamberlain Share The planned Phase Ib/2a clinical trial (IND 178511) is designed to investigate the safety, tolerability, and preliminary efficacy of STAR-001 in combination with spironolactone in patients with recurrent GBM, one of the deadliest and most aggressive forms of brain cancer. GBM represents approximately 15% of all brain tumors and has a median survival of approximately 12 months from initial diagnosis, with fewer than 5% of patients surviving beyond five years. "This FDA clearance represents a significant milestone for Starlight Therapeutics and our mission to bring innovative treatment options to patients facing the most challenging forms of brain and CNS cancers," said Dr. Marc Chamberlain, Chief Medical Officer of Starlight Therapeutics. "GBM remains one of the most difficult cancers to treat, with virtually no meaningful therapeutic advances in nearly 17 years. We believe our unique combination approach has the potential to offer new hope for patients and their families while advancing a novel mechanism to challenge these recurrent brain cancers." Targeting GBM Through Innovative Synthetic Lethality STAR-001 (also referred to as LP-184 when focused on other solid tumor indications) is a synthetically lethal, brain-penetrant, novel DNA-damaging agent that has demonstrated promising preclinical activity against various solid tumors, including pediatric and adult brain cancers. Lantern Pharma has previously been awarded both FDA Orphan Drug Designation and FDA Fast Track Designation for STAR-001 in GBM, underscoring the significant unmet medical need and the drug's potential to address it. An existing Phase 1a trial to determine safety, dosing, the maximum tolerated dose (MTD) and tolerability across a range of solid tumors, including GBM, is currently underway and expected to complete enrollment in the current quarter. This trial is expected to help establish a baseline dosing level and expectations of drug-concentration in tumor and plasma for future clinical trials, including those being planned by Starlight Therapeutics. The combination of STAR-001 with spironolactone, an existing FDA approved drug, represents a scientifically rational approach to treating GBM. STAR-001 is a blood-brain barrier permeable small molecule that leverages synthetic lethality to exploit DNA damage repair (DDR) deficiencies, particularly those overexpressing PTGR1. Approximately 60% of GBM cells overexpress PTGR1 levels sufficient to activate STAR-001. Spironolactone significantly enhances this therapeutic effect by inducing degradation of ERCC3, a critical protein involved in nucleotide excision repair (NER). This mechanism leads to NER deficiency (NERD), making GBM cells significantly more sensitive to STAR-001 and less capable of repairing the DNA damage caused by the administration of STAR-001. This synergistic approach is particularly promising in GBM which has often become resistant to therapies in the recurrent setting. AI-Driven Drug Development Platform Starlight Therapeutics was formed to pursue the focused clinical development of central nervous system (CNS) oncology indications developed and advanced through Lantern Pharma's proprietary artificial intelligence drug development platform, RADR®. This AI-driven approach enables the identification of optimal drug-cancer combinations and patient populations most likely to benefit from treatment, significantly reducing the time and cost typically associated with traditional drug development. "The clearance of this IND demonstrates the power of our efficient, data-driven drug development model in identifying promising therapeutic opportunities in areas of high unmet medical need," said Panna Sharma, President and CEO of Lantern Pharma. "Through Starlight Therapeutics, we are positioned to dedicate focused resources and expertise to advancing treatments for some of the most challenging cancers affecting the brain and central nervous system in both adults and children, while developing meaningful therapies that can reach patients in an accelerated timeline compared to traditional drug development processes." Market Opportunity and Next Steps With GBM representing an annual market opportunity of $3 to $5 billion globally and case numbers accelerating worldwide, there is an urgent need for innovative treatment approaches. The current standard of care has remained largely unchanged for over 15 years, highlighting the critical importance of novel therapeutic strategies like the STAR-001 combination. Starlight is targeting commencement of the Phase Ib/2a trial in late 2025 or early 2026, subject to additional funding, and plans to provide regular updates on trial preparation, patient enrollment progress, and preliminary data as they become available. About Glioblastoma Multiforme (GBM) Glioblastoma multiforme is the most common and aggressive form of primary brain tumor in adults, accounting for approximately 15% of all brain tumors. Despite aggressive multimodal treatment including surgery, radiation, and chemotherapy, the prognosis remains extremely poor, with a median survival of only 12 months and a five-year survival rate of less than 5%. The blood-brain barrier presents a significant challenge in treating GBM, as most therapeutic agents cannot effectively penetrate brain tissue. About Starlight Therapeutics Starlight Therapeutics is a wholly owned subsidiary of Lantern Pharma Corp., specifically focused on the clinical development of innovative treatments for central nervous system oncology indications. The company leverages Lantern Pharma's proprietary AI drug development platform to identify and advance promising therapeutic combinations for adult and pediatric patients with brain and CNS cancers. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR® uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; estimates and plans regarding our subsidiary Starlight Therapeutics Inc. and the product candidate STAR-001; our strategic plans to advance the development of our drug candidates, including STAR-001, and our antibody drug conjugate (ADC) development program; estimates regarding the development timing for STAR-001; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Business Insider
16-07-2025
- Business Insider
The Sandbox Launches Largest LAND Sale to Date on GBM Auctions
Over 110 LANDs and 220 avatars go live in the metaverse's most IP-rich auction to date, all powered by GBM's Win-Win protocol. The Sandbox, the leading social gaming metaverse, is partnering exclusively once again, with GBM Auctions to launch its largest set of auctions for LAND to date. The drop includes 110 LANDs (including 4 Estates exclusive to this sale) and 220 branded avatars across 22 IPs, all distributed via GBM Auctions' Win-Win auction protocol. In a first for The Sandbox, auctions will precede its own platform sale, highlighting a shift in how LAND is brought to market and underscoring GBM's role as the auction layer for Web3-native asset distribution. A Fairer and More Transparent Way to Buy LAND Traditional NFT sales often reward speed or capital, using first-come-first-serve mechanics or gas wars. GBM's Win-Win model changes the experience by rewarding every participant rather than just the final buyer. With GBM's Win-Win auction model, even outbid participants are rewarded. Every bid: Is fully refunded if outbid Comes with an incentive reward based on auction mechanics Contributes to true, onchain price discovery The Win-Win model flips the typical auction dynamic on its head. Instead of punishing latecomers or smaller bidders, it turns participation itself into a value-generating act, transforming auctions from winner-takes-all battles into high-engagement, trustless events where every bid matters and every bidder benefits. 'We're thrilled to bring this expanded LAND auction to our community for the Training Grounds LAND sale through GBM. Their Win-Win Auction model offers a new, gamified way for people to enter the ecosystem and build the metaverse with us. ' - Cédric Neumann, The Sandbox NFT Sales Director 'This is the biggest LAND and avatar sale we've hosted with The Sandbox, and a blueprint for how branded assets should be distributed in the open metaverse.' - Hugo McDonaugh, Co-Founder & CEO, GBM What's in the Drop The auction will feature 80 regular LANDs, 26 premium LANDs, and four estates, including three 3x3 plots and one 6x6 estate; the estates are exclusively available through GBM and not sold on The Sandbox's platform. In addition to the LAND, this drop includes 220 avatars from 22 different brands, with 10 avatars per brand available via auction. Participating IPs include well-known names like Cirque du Soleil, with more to be revealed during the campaign. Timeline and Activation The Sandbox and GBM kicked off proceedings by co-host a live X Space on 14 July, featuring NFT Sales Director Cédric Neumann, Stream Product Owner PandaPops, and GBM Co-Founder Hugo McDonaugh, who discussed the drop and how the Win-Win auction model works. Users can check out the recording of the Spaces here. The X Space was followed by The Sandbox's blog post and email campaign to its whole community base. The auctions officially went live on 15 July at 2:00 PM UTC and is running for seven days, closing on 22 July. All auctions are primary listings only; assets aren't available through open marketplaces or secondary resale during this campaign. Why This Drop Matters This is the first time The Sandbox is leading with auctions before launching the public sale on its own platform, a shift from its typical sales sequence. Estates included in this drop are also exclusively available via GBM, making them inaccessible through any other marketplace or channel. With avatars and LANDs from more than 20 brands, this is one of the most multi-dimensional and IP-rich activations to date. Powered by GBM's protocol-native incentive system, the drop ensures every bidder receives value, not just the final winner. How to Join the Auction To view and participate in the auctions, once live, users can visit: All auctions will use GBM's Win-Win model, ensuring every bid counts, and every participant receives value, even if they're outbid. About GBM Auctions GBM is the auction protocol redefining how value is distributed onchain. At the heart of GBM is its innovative Win-Win auction model, which rewards every participant, not just the winner. This sets a new standard for price discovery and value alignment across Web3. GBM has powered over $200M in volume and distributed more than $6M in rewards to date. About The Sandbox The Sandbox, a subsidiary of Animoca Brands, is an immersive metaverse platform in which users play, create, and monetize unique experiences alongside their favorite brands, IPs, and celebrities across gaming, entertainment, music, art, and more. The Sandbox leverages web3 technologies to fully enable end-user creation and creator economies, disrupting existing platforms by providing both players and creators with true ownership of their assets, creations, and rewards as non-fungible tokens (NFTs). Over 400 partners have joined The Sandbox, including Warner Music Group, Gucci, Ubisoft, Paris Hilton, The Walking Dead, Snoop Dogg, Attack on Titan, Lacoste, Steve Aoki, The Smurfs, and many more. For more information, users can visit and follow the regular updates on Twitter, Medium, and Discord. Disclaimer - The GBM token is a utility token for participation in the GBM ecosystem. It is not an investment, security, or financial product. Participation in the GBM IDO does not guarantee profits or returns.
